'Sarepta's like a curse on me': FDA commissioner Califf says - STAT News
FDA commissioner Robert Califf defends agency's standards amid criticism for granting full approval to Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys and Travere Therapeutics’ drug Filspari for IgAN, despite failed Phase 3 trials.
Reference News
'Sarepta's like a curse on me': FDA commissioner Califf says - STAT News
FDA commissioner Robert Califf defends agency's standards amid criticism for granting full approval to Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys and Travere Therapeutics’ drug Filspari for IgAN, despite failed Phase 3 trials.